Controversies in technique selection for endoscopic resection of Barrett's neoplasia

IF 5.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Julia L. Gauci, Yusuke Fujiyoshi, Tony He, Christopher Teshima
{"title":"Controversies in technique selection for endoscopic resection of Barrett's neoplasia","authors":"Julia L. Gauci,&nbsp;Yusuke Fujiyoshi,&nbsp;Tony He,&nbsp;Christopher Teshima","doi":"10.1016/j.bpg.2026.102120","DOIUrl":null,"url":null,"abstract":"<div><div>Barrett's esophagus-related neoplasia is now predominantly managed with endoscopic eradication therapy. This strategy combines endoscopic resection of visible lesions with ablation of residual Barrett's mucosa, offering excellent safety and long-term disease control. Two endoscopic resection techniques are used in current practice: endoscopic mucosal resection and endoscopic submucosal dissection. Existing guideline recommendations for technique selection vary but are largely based on the suspected depth of invasion and preference for R0 resection. However, the unique biological and clinical features of Barrett's challenge this framework. Neoplasia arises within a field of metaplastic change, and the ultimate goal is not simply complete resection but durable eradication of disease. The traditional oncologic endpoint, R0 resection, may be less meaningful in this context, while more clinically relevant outcomes, such as recurrence, disease-free survival, and patient-centred measures, remain inconsistently defined and reported. Furthermore, technical and procedural considerations, including histopathological accuracy, safety, and resource use, add further complexity to decision-making. This review explores the evolving evidence, highlights ongoing debates in technique selection for Barrett's neoplasia, and proposes considerations to inform patient-centred clinical decision-making and future research priorities.</div></div>","PeriodicalId":56031,"journal":{"name":"Best Practice & Research Clinical Gastroenterology","volume":"82 ","pages":"Article 102120"},"PeriodicalIF":5.2000,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521691826000302","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Barrett's esophagus-related neoplasia is now predominantly managed with endoscopic eradication therapy. This strategy combines endoscopic resection of visible lesions with ablation of residual Barrett's mucosa, offering excellent safety and long-term disease control. Two endoscopic resection techniques are used in current practice: endoscopic mucosal resection and endoscopic submucosal dissection. Existing guideline recommendations for technique selection vary but are largely based on the suspected depth of invasion and preference for R0 resection. However, the unique biological and clinical features of Barrett's challenge this framework. Neoplasia arises within a field of metaplastic change, and the ultimate goal is not simply complete resection but durable eradication of disease. The traditional oncologic endpoint, R0 resection, may be less meaningful in this context, while more clinically relevant outcomes, such as recurrence, disease-free survival, and patient-centred measures, remain inconsistently defined and reported. Furthermore, technical and procedural considerations, including histopathological accuracy, safety, and resource use, add further complexity to decision-making. This review explores the evolving evidence, highlights ongoing debates in technique selection for Barrett's neoplasia, and proposes considerations to inform patient-centred clinical decision-making and future research priorities.
内镜下巴雷特瘤切除术技术选择的争议
Barrett食管相关肿瘤现在主要采用内镜根除治疗。该策略将内镜下可见病变切除与残余Barrett粘膜消融相结合,具有良好的安全性和长期的疾病控制。在目前的实践中使用了两种内镜切除技术:内镜粘膜切除术和内镜粘膜下夹层切除术。现有的指南对技术选择的建议各不相同,但主要是基于怀疑的侵犯深度和对R0切除术的偏好。然而,巴雷特氏病独特的生物学和临床特征挑战了这一框架。肿瘤发生在化生变化的范围内,最终目标不是简单地完全切除,而是持久地根除疾病。在这种情况下,传统的肿瘤终点R0切除可能意义不大,而更多临床相关的结局,如复发、无病生存和以患者为中心的措施,仍然没有一致的定义和报道。此外,技术和程序方面的考虑,包括组织病理学的准确性、安全性和资源利用,进一步增加了决策的复杂性。本综述探讨了不断发展的证据,强调了巴雷特瘤变技术选择的持续争论,并提出了以患者为中心的临床决策和未来研究重点的考虑因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.50
自引率
0.00%
发文量
23
审稿时长
69 days
期刊介绍: Each topic-based issue of Best Practice & Research Clinical Gastroenterology will provide a comprehensive review of current clinical practice and thinking within the specialty of gastroenterology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书